JP2010519205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519205A5 JP2010519205A5 JP2009549627A JP2009549627A JP2010519205A5 JP 2010519205 A5 JP2010519205 A5 JP 2010519205A5 JP 2009549627 A JP2009549627 A JP 2009549627A JP 2009549627 A JP2009549627 A JP 2009549627A JP 2010519205 A5 JP2010519205 A5 JP 2010519205A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- dose
- cell
- immunogenic
- doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90198007P | 2007-02-15 | 2007-02-15 | |
| US60/901,980 | 2007-02-15 | ||
| PCT/US2008/002044 WO2008100598A2 (en) | 2007-02-15 | 2008-02-15 | A method for enhancing t cell response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013242826A Division JP2014043459A (ja) | 2007-02-15 | 2013-11-25 | Ｔ細胞応答の増強方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519205A JP2010519205A (ja) | 2010-06-03 |
| JP2010519205A5 true JP2010519205A5 (https=) | 2011-03-31 |
| JP5755839B2 JP5755839B2 (ja) | 2015-07-29 |
Family
ID=39690701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549627A Expired - Fee Related JP5755839B2 (ja) | 2007-02-15 | 2008-02-15 | Ｔ細胞応答の増強方法 |
| JP2013242826A Pending JP2014043459A (ja) | 2007-02-15 | 2013-11-25 | Ｔ細胞応答の増強方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013242826A Pending JP2014043459A (ja) | 2007-02-15 | 2013-11-25 | Ｔ細胞応答の増強方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080199485A1 (https=) |
| EP (2) | EP2129389B1 (https=) |
| JP (2) | JP5755839B2 (https=) |
| CN (2) | CN101657213B (https=) |
| AU (1) | AU2008216669B2 (https=) |
| CA (1) | CA2678353A1 (https=) |
| ES (1) | ES2527412T3 (https=) |
| MX (1) | MX2009008620A (https=) |
| WO (1) | WO2008100598A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| MX2007015933A (es) * | 2005-06-17 | 2008-04-21 | Mannkind Corp | Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales. |
| WO2008121354A1 (en) | 2007-03-30 | 2008-10-09 | Duke University | A method of modulating the activity of a nucleic acid molecule |
| WO2009155332A1 (en) * | 2008-06-17 | 2009-12-23 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
| DE102008061522A1 (de) * | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| US20110257458A1 (en) * | 2008-12-24 | 2011-10-20 | Cedars-Sinai Medical Center | Method of using tumor cell debris to reduce brain tumor recurrence or growth |
| IN2012DN02345A (https=) | 2009-09-16 | 2015-08-21 | Univ Duke | |
| AU2010310468A1 (en) | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| US20130108661A1 (en) | 2010-02-05 | 2013-05-02 | Mount Sinai School Of Medicine | Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells |
| EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
| US20150037374A1 (en) * | 2013-07-31 | 2015-02-05 | Csl Limited | Anti-tumor compositions and uses thereof |
| WO2015161094A1 (en) | 2014-04-16 | 2015-10-22 | Duke University | Electrospun cationic nanofibers and methods of making and using the same |
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| SG10201912485PA (en) | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017079537A1 (en) | 2015-11-04 | 2017-05-11 | Duke University | Polycationic polymers for use in treating and detecting cancer |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| KR20190044029A (ko) | 2016-05-18 | 2019-04-29 | 알버트 아인슈타인 컬리지 오브 메디슨, 인크. | 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법 |
| CA3019005A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US12447464B2 (en) | 2016-12-22 | 2025-10-21 | Duke University | Polycationic microfibers and methods of using the same |
| WO2018124005A1 (ja) | 2016-12-27 | 2018-07-05 | 中外製薬株式会社 | 被験物質の免疫原性を評価する方法 |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
| CN111135310B (zh) * | 2019-12-24 | 2021-05-07 | 江苏省人民医院（南京医科大学第一附属医院） | 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用 |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN116262779A (zh) * | 2021-12-14 | 2023-06-16 | 深圳先进技术研究院 | 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778879A (en) * | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
| DE4143467C2 (de) | 1991-05-17 | 1995-02-09 | Max Planck Gesellschaft | Peptidmotiv und dessen Verwendung |
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| DE4423392A1 (de) | 1994-07-04 | 1996-01-11 | Birsner & Grob Biotech Gmbh | Verfahren zur Identifizierung antigener Peptide |
| JPH10512155A (ja) | 1995-02-28 | 1998-11-24 | マックス−プランク−ゲゼルシャフト ツル フェルデルング デアヴイッセンシャフテン エー．ファウ．ベルリン | 癌およびその他の過形成を治療する薬剤 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| AU727955B2 (en) * | 1996-06-12 | 2001-01-04 | Yajun Guo | Cellular vaccines and immunotherapeutics and methods for their preparation |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| EP2286831A1 (en) | 1997-07-10 | 2011-02-23 | Mannkind Corporation | A method of inducing a CTL response |
| US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| DK1062341T3 (da) * | 1998-03-16 | 2008-11-03 | Alk Abello As | Muterede rekombinante allergener |
| US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| US20020165176A1 (en) * | 2000-05-01 | 2002-11-07 | Haynes Joel R. | Nucleic acid immunization |
| GB0023008D0 (en) * | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| JP2005505242A (ja) * | 2001-03-07 | 2005-02-24 | マンカインド コーポレイション | 癌用抗新生血管系調製物 |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US8637305B2 (en) * | 2001-11-07 | 2014-01-28 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
| NZ519363A (en) * | 2002-06-05 | 2004-02-27 | Agres Ltd | A novel drug dosing regimen |
| WO2004022709A2 (en) | 2002-09-06 | 2004-03-18 | Mannkind Corporation | Epitope sequences |
| DE602004028468D1 (de) | 2003-06-17 | 2010-09-16 | Mannkind Corp | Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke |
| AU2004249254B2 (en) | 2003-06-17 | 2010-07-08 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
| US6997074B2 (en) | 2003-10-30 | 2006-02-14 | Eaton Corporation | Prediction of destination gear for progressive shift feature |
| EP1773402A2 (en) * | 2004-06-17 | 2007-04-18 | Mannkind Corporation | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
| US8202841B2 (en) * | 2004-06-17 | 2012-06-19 | Mannkind Corporation | SSX-2 peptide analogs |
| EP1838342A2 (en) * | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| EP1838338A2 (en) | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| US20060165711A1 (en) | 2004-12-29 | 2006-07-27 | Bot Adrian I | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
| AU2005321898B2 (en) | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| WO2006120474A2 (en) * | 2005-05-13 | 2006-11-16 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against tumor antigens |
-
2008
- 2008-02-15 EP EP08725654.1A patent/EP2129389B1/en not_active Not-in-force
- 2008-02-15 CN CN200880012207.3A patent/CN101657213B/zh not_active Expired - Fee Related
- 2008-02-15 AU AU2008216669A patent/AU2008216669B2/en not_active Ceased
- 2008-02-15 CN CN201410026166.0A patent/CN103736086A/zh active Pending
- 2008-02-15 ES ES08725654.1T patent/ES2527412T3/es active Active
- 2008-02-15 MX MX2009008620A patent/MX2009008620A/es active IP Right Grant
- 2008-02-15 EP EP12165994A patent/EP2481418A1/en not_active Withdrawn
- 2008-02-15 WO PCT/US2008/002044 patent/WO2008100598A2/en not_active Ceased
- 2008-02-15 JP JP2009549627A patent/JP5755839B2/ja not_active Expired - Fee Related
- 2008-02-15 CA CA002678353A patent/CA2678353A1/en not_active Abandoned
- 2008-02-15 US US12/070,156 patent/US20080199485A1/en not_active Abandoned
-
2013
- 2013-11-25 JP JP2013242826A patent/JP2014043459A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519205A5 (https=) | ||
| Wu et al. | Overview of vaccine adjuvants | |
| Kayraklioglu et al. | CpG oligonucleotides as vaccine adjuvants | |
| Otten et al. | Enhancement of DNA vaccine potency in rhesus macaques by electroporation | |
| Vasilakos et al. | The use of Toll-like receptor 7/8 agonists as vaccine adjuvants | |
| Vacchelli et al. | Trial watch: Peptide vaccines in cancer therapy | |
| Johansen et al. | Lympho-geographical concepts in vaccine delivery | |
| Tomai et al. | TLR7/8 agonists as vaccine adjuvants | |
| Akache et al. | Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice | |
| Higgins et al. | Immunostimulatory DNA as a vaccine adjuvant | |
| CN114762695A (zh) | 具有免疫增强活性的包含寡核苷酸的复合体及其用途 | |
| Feng et al. | Novel polysaccharide from Radix Cyathulae officinalis Kuan can improve immune response to ovalbumin in mice | |
| Dong et al. | Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice | |
| MX2011012147A (es) | Inmunoterapia de vacuna. | |
| JP2015512866A5 (https=) | ||
| JP2008000001A (ja) | 免疫刺激オリゴヌクレオチドおよびその医薬用途 | |
| Lee et al. | Enhanced anti-tumor immunotherapy by dissolving microneedle patch loaded ovalbumin | |
| JP2006502228A5 (https=) | ||
| US20080014211A1 (en) | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes | |
| JP2012524793A (ja) | 免疫調節性生体分子を組み合わせて送達するためのヒドロゲル | |
| Lee et al. | Biodegradable cationic polycarbonates as vaccine adjuvants | |
| Luo et al. | Nanomaterials in tuberculosis DNA vaccine delivery: historical perspective and current landscape | |
| Wang et al. | Innate endogenous adjuvants prime to desirable immune responses via mucosal routes | |
| CN103861099A (zh) | 疫苗佐剂、疫苗组合物与牛樟芝子实体之用途 | |
| JP2020182486A5 (https=) |